Global Kidney Renal Cancer Drugs Market Insights, Size, and Forecast By Route of Administration (Oral, Intravenous, Subcutaneous), By Cancer Stage (Localized, Regional, Metastatic), By Patient Demographics (Adult Male, Adult Female, Pediatric), By Drug Type (Targeted Therapy, Immunotherapy, Chemotherapy, Hormonal Therapy), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Kidney Renal Cancer Drugs Market is projected to grow from USD 9.1 Billion in 2025 to USD 17.8 Billion by 2035, reflecting a compound annual growth rate of 8.7% from 2026 through 2035. This robust growth trajectory is driven by a confluence of factors, including the increasing incidence of kidney cancer globally, advancements in diagnostic technologies leading to earlier detection, and the expanding pipeline of innovative therapeutic agents. The market encompasses a wide array of drug types, primarily focused on targeted therapies, immunotherapies, and traditional chemotherapies, addressing various cancer stages from localized to metastatic. Targeted therapy currently dominates the market, signifying a major shift towards more precise and effective treatments with reduced side effects compared to conventional cytotoxic chemotherapy. Escalating healthcare expenditure, particularly in developed economies, further fuels the market’s expansion as access to advanced and costly treatments improves. However, high development costs for new drugs, stringent regulatory approval processes, and the impending patent expirations of several blockbuster drugs pose significant restraints on market growth, potentially intensifying generic competition. Nonetheless, the rising awareness about kidney cancer, coupled with a focus on personalized medicine approaches, presents considerable opportunities for market players to innovate and expand their portfolios.
Global Kidney Renal Cancer Drugs Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
North America stands as the dominant region in the global kidney renal cancer drugs market. This leadership is attributed to several factors including a well-established healthcare infrastructure, high prevalence of kidney cancer, significant R&D investments by pharmaceutical companies, and favorable reimbursement policies. The region also benefits from a high adoption rate of advanced therapies and a strong presence of key market players. Conversely, Asia Pacific is identified as the fastest growing region. This rapid expansion is primarily driven by improving healthcare access, increasing disposable incomes, a large patient pool, and a growing awareness about cancer diagnosis and treatment. Furthermore, government initiatives aimed at improving healthcare infrastructure and rising medical tourism contribute to the region's accelerated growth. The market also sees growth propelled by a shift towards value based healthcare, encouraging the development of therapies that offer significant clinical benefits and improved patient outcomes. Emerging markets within Asia Pacific, particularly China and India, are becoming crucial growth engines due to their large populations and burgeoning healthcare sectors, attracting investments from global pharmaceutical giants.
Key players such as AstraZeneca, Merck & Co, Bayer, Pfizer, Sanofi, Incyte, Ipsen, Exelixis, Amgen, and Eli Lilly are actively engaged in strategic initiatives to consolidate their market positions. These strategies include extensive R&D investments to discover novel compounds, M&A activities to acquire promising drug candidates and technologies, and strategic collaborations to co-develop and commercialize new therapies. For instance, many companies are focusing on expanding indications for their existing drugs and exploring combination therapies to enhance efficacy and overcome drug resistance. There is also a strong emphasis on developing biomarkers to identify patient populations most likely to respond to specific treatments, aligning with the precision medicine paradigm. Furthermore, geographical expansion into underserved markets, particularly in emerging economies, represents a key growth strategy. The competitive landscape is characterized by continuous innovation and a strong focus on clinical trials to demonstrate superior efficacy and safety profiles of new drugs, ultimately aiming to capture a larger share of the evolving kidney renal cancer drugs market.
Quick Stats
Market Size (2025):
USD 9.1 BillionProjected Market Size (2035):
USD 17.8 BillionLeading Segment:
Targeted Therapy (45.2% Share)Dominant Region (2025):
North America (45.8% Share)CAGR (2026-2035):
8.7%
Global Kidney Renal Cancer Drugs Market Emerging Trends and Insights
Immunotherapy Pipeline Expansion
Immunotherapy is rapidly transforming the kidney renal cancer landscape, driving significant pipeline expansion within the global drugs market. This trend reflects a growing understanding of tumor immunology and a shift towards therapies that leverage the body’s own immune system to fight cancer. Researchers are exploring novel checkpoint inhibitors, adoptive cell therapies like CAR T cells, and oncolytic viruses, all designed to enhance immune recognition and destruction of renal cancer cells. This intensified research and development activity is fueling a wave of new drug candidates entering clinical trials, aiming to improve efficacy and reduce side effects compared to traditional treatments. The focus is on developing combination therapies and identifying biomarkers to personalize treatments, further broadening the immunotherapy toolkit available for kidney renal cancer patients.
Targeted Therapy Combinations
Targeted therapy combinations are a significant trend in the global kidney renal cancer drugs market, reflecting a strategic shift towards more effective and personalized treatment regimens. Historically, single agent targeted therapies like VEGF or mTOR inhibitors showed promise, but resistance often developed, limiting long term efficacy. The concurrent administration of two or more targeted agents with distinct mechanisms of action is now increasingly explored and adopted. This approach aims to overcome drug resistance by simultaneously blocking multiple signaling pathways critical for tumor growth and survival. Combinations often involve therapies that inhibit different targets within the same pathway, or therapies that target separate, complementary pathways. For instance, combining a VEGF inhibitor with an mTOR inhibitor can demonstrate synergistic effects, leading to improved progression free survival and overall response rates for patients with advanced renal cell carcinoma. This trend emphasizes maximizing therapeutic benefits and broadening the patient population that can achieve durable responses.
Biomarker Driven Precision Oncology
Biomarker driven precision oncology is a transformative trend in the global kidney renal cancer drugs market. Historically, treatment was largely empirical. Now, clinicians increasingly leverage specific molecular signatures within a patient’s tumor to guide therapeutic choices. This involves identifying unique biomarkers indicating disease presence, progression, or susceptibility to certain targeted therapies. For instance, mutations in genes like VHL or specific angiogenesis pathway markers can predict responses to particular tyrosine kinase inhibitors or immunotherapy. This approach minimizes trial and error, enhancing treatment efficacy while reducing adverse effects for individual patients. It fosters the development of companion diagnostics alongside novel targeted agents, tailoring therapeutic strategies to the patient’s unique tumor biology rather than a one size fits all approach, ultimately improving patient outcomes and quality of life.
What are the Key Drivers Shaping the Global Kidney Renal Cancer Drugs Market
Advancements in Targeted Therapies and Immunotherapies
Advancements in targeted therapies and immunotherapies are revolutionizing the Global Kidney Renal Cancer Drugs Market. These innovative treatments offer enhanced precision and efficacy compared to traditional chemotherapy. Targeted therapies meticulously block specific molecular pathways crucial for tumor growth and survival, leading to more potent tumor reduction and fewer systemic side effects. Immunotherapies, on the other hand, harness the body's own immune system to recognize and destroy cancer cells. This paradigm shift provides durable responses and improves patient outcomes, particularly for advanced or refractory cases. The continuous discovery of novel targets and immune modulators is expanding treatment options, increasing therapeutic success rates, and driving the demand for these sophisticated drugs globally.
Rising Incidence and Prevalence of Kidney Cancer
The increasing occurrence of kidney cancer significantly propels the global market for renal cancer drugs. As more individuals are diagnosed with kidney cancer each year, the demand for effective treatments naturally escalates. Factors such as improved diagnostic tools and an aging global population contribute to this rise in incidence. Furthermore, lifestyle changes and environmental factors are also implicated in the growing prevalence of the disease. This surge in patient numbers directly translates into a greater need for both established and novel therapeutic agents, including targeted therapies, immunotherapies, and traditional chemotherapies. Consequently, pharmaceutical companies are driven to invest more in research and development, aiming to address this growing patient population with advanced and more efficacious drug solutions.
Increased R&D Investment and Pipeline Expansion
Companies are dedicating significant resources to research and development, a key driver in the global kidney renal cancer drugs market. This intensified investment fuels the discovery of novel therapeutic agents and the refinement of existing treatments. A robust pipeline of new drugs, including targeted therapies, immunotherapies, and combination regimens, is emerging as a direct result. These innovative treatments address unmet medical needs, offering improved efficacy, reduced side effects, and better patient outcomes. Expanding the pipeline is crucial for sustainable market growth, as it provides a continuous stream of potentially life changing medications. This commitment to innovation is critical for the evolving treatment landscape and for addressing the complexities of kidney renal cancer.
Global Kidney Renal Cancer Drugs Market Restraints
High Cost of Novel Therapies and Reimbursement Challenges
The high cost of novel therapies presents a significant barrier to market growth. These innovative treatments, while offering improved outcomes for kidney renal cancer patients, often come with premium price tags. This elevated expense directly impacts patient access, especially in regions with limited healthcare budgets or inadequate insurance coverage. Reimbursement challenges further exacerbate the issue. Obtaining approval and sufficient coverage from payers for these expensive drugs can be a lengthy and complex process, sometimes resulting in partial or no reimbursement. This financial burden on healthcare systems and individual patients can delay or prevent the adoption of new therapies, hindering their widespread availability and limiting the overall market expansion for advanced kidney renal cancer drugs.
Limited Awareness and Early Diagnosis in Developing Regions
Limited awareness and early diagnosis significantly restrict the global kidney renal cancer drugs market in developing regions. Many individuals in these areas remain undiagnosed until their cancer reaches advanced stages, often due to a lack of public health campaigns and educational initiatives about kidney cancer symptoms and risk factors. Primary healthcare providers may also lack adequate training to recognize early signs of the disease, leading to delayed referrals to specialists. Furthermore, limited access to advanced diagnostic tools like imaging and sophisticated laboratory tests in remote or underserved areas hinders accurate and timely diagnosis. By the time patients are identified, the disease may have progressed beyond the point where early intervention drugs are most effective, reducing the potential patient pool for these treatments. This diagnostic gap means fewer patients receive appropriate medication, impeding market expansion.
Global Kidney Renal Cancer Drugs Market Opportunities
Novel Therapeutic Strategies for Refractory and Treatment-Resistant Kidney Renal Cancer
The global kidney renal cancer drugs market presents a significant opportunity in pioneering novel therapeutic strategies for patients whose disease is refractory or treatment-resistant. A substantial and growing number of patients face poor prognoses as existing standard therapies often fail to control advanced or persistent kidney cancer. This profound unmet medical need creates a strong imperative and demand for truly innovative treatments that can overcome existing resistance mechanisms and deliver durable clinical benefits. The opportunity lies in developing new targeted agents, advanced immunotherapies, or effective combination regimens specifically designed to address these challenging patient populations. Success in this area promises not only to dramatically improve patient survival and quality of life, but also to capture a crucial and high-value segment of the market. Furthermore, rapidly expanding regions such as Asia Pacific underscore the increasing global demand for effective solutions to these difficult to treat kidney cancers, making innovation in this specific area particularly promising for market players seeking substantial growth.
Precision Medicine and Biomarker-Driven Therapies for Non-Clear Cell Renal Cell Carcinoma
The global kidney renal cancer drugs market presents a compelling opportunity in precision medicine and biomarker driven therapies for non clear cell renal cell carcinoma. This distinct and often aggressive subtype represents a significant unmet need, as its molecular drivers differ from clear cell variants, limiting the efficacy of current broad spectrum treatments. The development of targeted therapies based on specific biomarkers found in non clear cell RCC allows for highly personalized treatment strategies. Identifying these unique biological markers facilitates patient stratification, ensuring the right drug reaches the right patient. This approach promises enhanced therapeutic responses, reduced side effects, and ultimately improved survival rates for a patient population with historically poor prognoses. Leveraging advances in molecular diagnostics and genomic profiling is crucial to unlock these precise interventions. The substantial patient population in rapidly expanding regions like Asia Pacific creates immense demand for these innovative, tailored solutions, making non clear cell RCC a prime target for drug development and investment to transform patient care globally.
Global Kidney Renal Cancer Drugs Market Segmentation Analysis
Key Market Segments
By Drug Type
- •Targeted Therapy
- •Immunotherapy
- •Chemotherapy
- •Hormonal Therapy
By Cancer Stage
- •Localized
- •Regional
- •Metastatic
By Route of Administration
- •Oral
- •Intravenous
- •Subcutaneous
By Patient Demographics
- •Adult Male
- •Adult Female
- •Pediatric
Segment Share By Drug Type
Share, By Drug Type, 2025 (%)
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Hormonal Therapy
www.makdatainsights.com
Why is Targeted Therapy dominating the Global Kidney Renal Cancer Drugs Market?
Targeted therapy holds the largest share primarily due to its precision in addressing the specific molecular pathways involved in kidney renal cancer growth. These advanced drugs offer superior efficacy by directly interfering with cancer cell proliferation while often presenting a more favorable side effect profile compared to conventional treatments. Continuous innovation and the introduction of new agents in this category further solidify its leading position as the preferred first line and subsequent treatment option for many patients.
How do cancer stages influence treatment strategies in the Global Kidney Renal Cancer Drugs Market?
Cancer stage significantly dictates the therapeutic approach, profoundly impacting the demand for different drug types. While localized disease might primarily involve surgical intervention, regional and especially metastatic stages drive the substantial need for systemic drug therapies. Metastatic kidney cancer, in particular, necessitates advanced treatments like targeted therapies and immunotherapies to manage disease progression and improve patient outcomes, making it a critical driver for market growth in advanced drug segments.
What factors contribute to the prevalent routes of administration in the Global Kidney Renal Cancer Drugs Market?
The choice of administration route is heavily influenced by drug efficacy requirements, patient convenience, and the nature of the therapy. Intravenous administration remains crucial for many potent targeted therapies and immunotherapies, ensuring immediate systemic availability and precise dosing, particularly in hospital or clinic settings. Oral formulations are increasingly sought after for their convenience, allowing for at home treatment and improving patient adherence, thereby expanding access and potentially reducing healthcare burden for long term management.
Global Kidney Renal Cancer Drugs Market Regulatory and Policy Environment Analysis
The global kidney renal cancer drugs market navigates a complex regulatory landscape shaped by stringent national and international policies. Regulatory bodies such as the US Food and Drug Administration, European Medicines Agency, and Japan's Pharmaceuticals and Medical Devices Agency demand rigorous clinical trial data spanning multiple phases for drug approval. Expedited pathways like Fast Track, Breakthrough Therapy, and Orphan Drug designations significantly accelerate reviews for therapies addressing unmet needs in serious conditions like renal cancer, offering incentives for development.
Pricing and reimbursement policies exhibit considerable regional variation, heavily influenced by health technology assessment bodies that evaluate drug cost-effectiveness. This creates access disparities and reimbursement challenges. Intellectual property protection remains critical, driving innovation but also contributing to high drug costs. Post market surveillance ensures ongoing safety monitoring. Harmonization efforts through initiatives like ICH guidelines streamline development, yet local requirements persist. The increasing acceptance of real world evidence for regulatory and reimbursement decisions is also a significant trend impacting market access and drug lifecycle management for novel kidney cancer treatments.
Which Emerging Technologies Are Driving New Trends in the Market?
The global kidney renal cancer drugs market is profoundly impacted by ongoing innovations and emerging technologies. Immunotherapies, particularly checkpoint inhibitors, remain a cornerstone, delivering durable responses and expanding treatment options for various stages. Targeted therapies continue to evolve, with new agents inhibiting specific molecular pathways to improve efficacy and reduce side effects.
Emerging technologies are set to redefine the landscape. Artificial intelligence and machine learning are streamlining drug discovery, accelerating candidate identification, and optimizing clinical trial design. Advanced genomic profiling and liquid biopsy techniques enable earlier detection and more precise treatment selection, paving the way for highly personalized medicine. Gene editing technologies like CRISPR hold immense potential for developing novel cell and gene therapies aimed at correcting underlying genetic drivers or enhancing anti tumor immunity. Companion diagnostics are becoming crucial, ensuring patients receive the most appropriate and effective therapies. These advancements promise improved patient outcomes and sustained market expansion.
Global Kidney Renal Cancer Drugs Market Regional Analysis
Global Kidney Renal Cancer Drugs Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
Dominant Region
North America · 45.8% share
North America decisively dominates the Global Kidney Renal Cancer Drugs Market, commanding a substantial 45.8% market share. This significant lead is propelled by several key factors. The region benefits from highly advanced healthcare infrastructure and robust research and development capabilities, fostering innovation in drug discovery and treatment modalities. Furthermore, high awareness levels regarding kidney cancer, coupled with early diagnosis initiatives, contribute to a larger patient pool accessing treatment. Favorable reimbursement policies for expensive oncology drugs also play a crucial role in driving market expansion. The presence of leading pharmaceutical companies and biotechnology firms concentrated in North America further solidifies its dominant position, ensuring a steady pipeline of novel therapies and consistent market penetration across the region.
Fastest Growing Region
Asia Pacific · 10.2% CAGR
Asia Pacific emerges as the fastest growing region in the global kidney renal cancer drugs market, demonstrating a robust CAGR of 10.2% during the forecast period of 2026-2035. This significant growth is fueled by several key factors. Rising prevalence of kidney cancer across the region coupled with improving diagnostic capabilities are crucial drivers. Furthermore increased healthcare expenditure and enhanced patient access to advanced therapies contribute substantially. The expansion of medical infrastructure and a growing awareness about early detection and treatment options are also propelling market expansion. Emerging economies within Asia Pacific are particularly contributing to this surge as their healthcare systems evolve and become more sophisticated.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical factors profoundly impact the kidney renal cancer drugs market. Political instability in key manufacturing regions can disrupt supply chains and increase production costs, affecting drug availability and pricing. Trade policies and intellectual property rights are critical; protectionist measures or weak patent enforcement in emerging economies can deter innovation and market entry for pharmaceutical companies. Regulatory landscapes vary globally, with different approval processes and pricing controls influencing market access and profitability. Geopolitical tensions or alliances can also influence research collaboration and market access for new drugs, particularly in specialized oncology fields.
Macroeconomic factors significantly shape the market. Economic growth and healthcare expenditure directly correlate with demand for expensive cancer drugs. Recessions or periods of slow growth can lead to budget cuts in healthcare systems, impacting drug reimbursement policies and patient access. Inflation can increase manufacturing and research costs, potentially leading to higher drug prices. Currency fluctuations affect pharmaceutical companies' revenues and profitability, especially those operating internationally. Interest rates influence investment in research and development, and overall economic stability is crucial for sustained market expansion.
Recent Developments
- March 2025
Pfizer and Sanofi announced a strategic partnership to co-develop and co-commercialize a novel bispecific antibody for advanced renal cell carcinoma (RCC). This collaboration aims to accelerate the drug's path to market and leverage both companies' expertise in oncology.
- September 2024
Exelixis launched a new next-generation tyrosine kinase inhibitor (TKI) for previously treated advanced RCC across major markets including the US and EU. The drug demonstrated superior progression-free survival in Phase 3 trials, offering a new treatment option for patients.
- July 2025
Bayer acquired a clinical-stage biotech company specializing in innovative immunotherapies for solid tumors, including kidney cancer. This acquisition strengthens Bayer's oncology pipeline with promising early-stage assets and expertise in immune-oncology.
- November 2024
Merck & Co. initiated a large-scale Phase 3 clinical trial evaluating a new combination therapy for frontline metastatic RCC, combining their blockbuster immunotherapy with a novel small molecule inhibitor. This strategic initiative aims to establish a new standard of care with potentially improved efficacy and tolerability.
Key Players Analysis
AstraZeneca, Merck, and Bayer lead the kidney renal cancer drugs market, utilizing innovative technologies like targeted therapies and immunotherapies. Their strategic initiatives include R&D investments and expanding clinical trials, driving market growth through new drug development and increased patient access. Pfizer, Sanofi, and Amgen also play crucial roles with diverse portfolios and pipeline assets.
List of Key Companies:
- AstraZeneca
- Merck & Co
- Bayer
- Pfizer
- Sanofi
- Incyte
- Ipsen
- Exelixis
- Amgen
- Eli Lilly
- Taiho Pharmaceutical
- Roche
- Seattle Genetics
- Bristol Myers Squibb
- Novartis
- Johnson & Johnson
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 9.1 Billion |
| Forecast Value (2035) | USD 17.8 Billion |
| CAGR (2026-2035) | 8.7% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 2: Global Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 3: Global Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 4: Global Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 5: Global Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 7: North America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 8: North America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 9: North America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 10: North America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 12: Europe Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 13: Europe Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 14: Europe Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 15: Europe Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 17: Asia Pacific Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 18: Asia Pacific Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 19: Asia Pacific Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 20: Asia Pacific Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 22: Latin America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 23: Latin America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 24: Latin America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 25: Latin America Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Drug Type, 2020-2035
Table 27: Middle East & Africa Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Cancer Stage, 2020-2035
Table 28: Middle East & Africa Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Route of Administration, 2020-2035
Table 29: Middle East & Africa Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Patient Demographics, 2020-2035
Table 30: Middle East & Africa Kidney Renal Cancer Drugs Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035